Understanding Pharmaceutical Sustainable Supply chains - A Case Study Application
Article Sidebar
Main Article Content
Abstract
Downloads
Article Details
1. Proposal of Policy for Free Access Periodics
Authors whom publish in this magazine should agree to the following terms:
a. Authors should keep the copyrights and grant to the magazine the right of the first publication, with the work simultaneously permitted under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 that allows the sharing of the work with recognition of the authorship of the work and initial publication in this magazine.
b. Authors should have authorization for assuming additional contracts separately, for non-exclusive distribution of the version of the work published in this magazine (e.g.: to publish in an institutional repository or as book chapter), with recognition of authorship and initial publication in this magazine.
c. Authors should have permission and should be stimulated to publish and to distribute its work online (e.g.: in institutional repositories or its personal page) to any point before or during the publishing process, since this can generate productive alterations, as well as increasing the impact and the citation of the published work (See The Effect of Free Access).
Proposal of Policy for Periodic that offer Postponed Free Access
Authors whom publish in this magazine should agree to the following terms:
a. Authors should keep the copyrights and grant to the magazine the right of the first publication, with the work simultaneously permitted under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 [SPECIFY TIME HERE] after the publication, allowing the sharing of the work with recognition of the authorship of the work and initial publication in this magazine.
b. Authors should have authorization for assuming additional contracts separately, for non-exclusive distribution of the version of the work published in this magazine (e.g.: to publish in institutional repository or as book chapter), with recognition of authorship and initial publication in this magazine.
c. Authors should have permission and should be stimulated to publish and to distribute its work online (e.g.: in institutional repositories or its personal page) to any point before or during the publishing process, since this can generate productive alterations, as well as increasing the impact and the citation of the published work (See The Effect of Free Access).
d. They allow some kind of open dissemination. Authors can disseminate their articles in open access, but with specific conditions imposed by the editor that are related to:
Version of the article that can be deposited in the repository:
Pre-print: before being reviewed by pairs.
Post-print: once reviewed by pairs, which can be:
The version of the author that has been accepted for publication.
The editor's version, that is, the article published in the magazine.
At which point the article can be made accessible in an open manner: before it is published in the magazine, immediately afterwards or if a period of seizure is required, which can range from six months to several years.
Where to leave open: on the author's personal web page, only departmental websites, the repository of the institution, the file of the research funding agency, among others.
References
ABBOUD, L.; HENSLYE, S. (2003). New prescription for drug makers: Update the Plant, The Wall Street Journal, September 3.
ALMOR, T.; TARBA, S.; BENJAMIN, H. (2009). Unmasking integration challenges: The case of Biogal’s acquisition by Teva Pharmaceutical Industries, International Studies of Management and Challenges, v. 39, n. 3, Fall 2009, p. 32-52
AUTRY, C. (2005). Formalization of reverse logistics programs: A strategy for managing liberalized returns, International Marketing Management, v. 34, p. 749-757
AVELLANET, J. (2010). John Avellanet on holistic pharma compliance and quality, June 2010, Available at: http://www.pharmaqbd.com
BIEDERMAN, D. (2010), Speeding Up, in Reverse, Journal of Commerce, New York.
BLACKBURN, J.; GUIDE, J.; DOUZA, G.; VAN WASSENHONE, L. (2004). “Reverse supply chains for commercial returns”, California Management Review, v. 46, n. 2, p. 6-22
BOWERSOX, D.; CLOSS, D. (1996). Logistical management: The integrated supply chain process, McGraw-Hill International Editions, London
BOWMAN, C.; AMBROSINI, V. (2000). Value creation versus value capture: towards a coherent definition of value integrity, British Journal of Management, v. 11, p. 1-15
CAMPBELL, J. (2007). Why Would Corporations Behave in Socially Responsible Ways? An Institutional Theory of Corporate Social Responsibility, Academy f Management Review, v. 32, n. 3, p. 946-967
CHEAH. E.; CHAN, W.; CHIENG, C. (2007). The corporate social responsibility of pharmaceutical product recalls: An empirical examination of US and UK markets, Journal of Business Ethics, v. 76, p. 427-449
CHASE, R. B. (1998). Operations Management Internationalization and Interdisciplinary Integration, International Journal of Operations & Production Management, v. 18, n. 7, p. 663-667
CNNMONEY.COM (2010), Drug Recalls Surge, Available at: www.cnn.com/2010/08/16/news/companies/drug_recall_surge/index.htm.
DALE, B. (2003). Managing Quality, 4th ed. Blackwell Publishing, Oxford
DE LA FUENTE, M. V.; ROS, L.; CARDÓS, M. (2008). Integrating Forward and Reverse Supply Chains: Application to a Metal-Mechanic Company, International Journal of Production Economics, v. 111, p. 782-792.
EDWARDS, A. (2010). Manufacturing the future, Integrated collaboration between CMOs and Sponsors, Available at: www.contractpharma.com/articles/2010/05/manufacturing-the-future
EISENHARDT, K. (1989). Building Theories from Case Study Research, Academy of Management Review, v. 14, n. 4, p. 532-550
EUROPEAN MEDICINES AGENCY (2007). An Analysis of Quality Product Defects in Centralized Procedure, Available at: http://www.ema.europa.eu
FASSOULA, E. (2005). Reverse logistics as a means of reducing the cost of quality, Total Quality Management & Business Excellence, v. 16, n. 5, p. 631-643
FOOD AND DRUG ADMINISTRATION, (2007). CDER Facts and Figures, Available at: http://www.fda.gov/Drugs/DrugSafety/default.htm
GOULDING, C. (2002). Grounded Theory, A Practical Guide Management. Business and Marketing Research, Sage Publications
GRAUNAUER, T.; SCHERRER-RATHJE, M.; FRIEDLI, T. (2009). A reference framework to sustainably implement operational excellence in the pharmaceutical industry, EurOMA 2009 Proceedings. Available at: www.euroma2009.org/Proceedings
GRI, (2011). Available at www.globalreporing.org
GRONROOS, C. (2008). Service logistics revisited: who creates value and who co-creates, European Business Review, v. 20, n. 4, p. 298-314
HART, S. (1997). Beyond greening, Harvard Business Review, n. 1, p. 66-76
HART, S.; MILSTEIN, M. (2003). Creating Sustainable Value, Academy of Management Executive, v. 17, n. 2, p. 55-69
HOWARD, I.; HUMBY, S. (2008). Embedding Corporate Responsibility into Supply: A Snapshot of Progress, European Management Journal, v. 26, p. 166-174
HUNTER, T. S.; DROEGE, M.; MARSH, W. A.; DROEGE, W. L. (2005). CE: Effectively managing pharmaceutical returns and waste, Drug Topics, v. 149, n. 2, p. 36.
IMS HEALTH, (2010). Available at: http://www.imshealth.com/portal/site/imshealth
INTERNATIONAL CONFERENCE ON HARMONIZATION: Available at: http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html
JORGENSEN, T. (2008). Towards more Sustainable Management Systems: through Life Cycle Management and Integration, Journal of Cleaner Production, v. 16, p. 1071-1080
KIRIDERA, S.; HASAN, M.; KERR, R. (2009). Exploring deeper Structures in Manufacturing Strategy formation Progress: A Qualitative Inquiry, International Journal of Operations & Production Management, v. 29, n. 4, p. 386-417
KUMAR, S.; DIEVENEY, E.; DIEVENEY, A. (2009). Reverse logistic process control measures for the pharmaceutical supply chain, International Journal of Productivity and Performance Management, v. 58, n. 2, p. 188-204
KUMAR, S.; PUTMAN, V. (2008). Cradle to cradle: reverse logistics and opportunities across three industry sectors, Int. Journal of Production Economics, v. 115, p. 305-315
KRUMWIEDE, D.; SHEU, C. (2002). A model for reverse logistics entry by third-party providers, Omega, v. 30, p. 325-333
LEVIS, A.; PAPAGEORGIOU, L. (2004). A hierarchical solution approach for multi-site capacity planning under uncertainty in the pharmaceutical industry, Computers and Chemical Engineering, v. 28, p. 707-725
LINTON, J.; KLASSEN, R.; JAYARAM, V. (2007). Sustainable Supply Chains: An Introduction, Journal of Operations Management, v. 25, p. 1075-1082.
MAHBOUBIAN-JONES, G. (2009). Toyota and lesson for pharma top managers, Available at: http://www.pharmaqbd.com
MAHLER, D. (2007). The Sustainable Supply Chain, Supply Chain Management Review, v. 11, n. 8, p. 59
MARKEY, M.; DAVIS, L. (2007). Exploring future competitive advantage through sustainable supply chains, International Journal of Physical Distribution & Logistics Management, v. 37, n. 9, p. 763-774
MCCONNELL, J.; NUNNALLY, B. K.; MCGARVEY, B. (2009). Variation – Past, Present, and Future, Journal of Validation Technology, Spring 2009, p. 37-42.
MEREDITH, J. (1998). Building Operations Management Theory through Case and Field Research, Journal of Operations Management, v. 16, n. 4, p. 441-454
MOLLENKOPF, D.; CLOSS, D.J. (2005). The Hidden Value in Reverse Logistics, Supply Chain Management Review, (July/August), p. 34-43
MOLLENKOPF, D.; RUSSO, I.; FRANKEL, R. (2011). Creating Value through Returns Management: Exploring the market-Operations Interface, Journal of Operations Management, Article in press.
MOLLENKOPF, D.; RUSSO, I.; FRANKEL, R. (2007). The Returns Management Process in Supply Chain Strategy, International Journal of Physical Distribution & Logistics Management, v. 37, n. 7, p. 568-592.
MORHARDT, J.; BAIRD, S.; FREEMAN, K. (2002). Scoring Corporate Environmental and Sustainability using GRI 2000, ISO 14031 and Other Criteria, Corporate Social Responsibility and Environmental Management, v. 9, p. 215-333
PAPAGEORGIOU, L.; ROTSTEIN, G.; SHAH, N. (2001). Strategic supply chain optimization of the pharmaceutical industries, Ind. Eng. Chem. Resources, v. 40, p. 275-286
PHARMACEUTICAL MARKET TRENDS, 2010-2014 (2010). http://www.pharmaceuticalmarketresearch.com/publications/general_industry/pharmaceutical_market_trends_2008_2012.html
PLUTA, P.; POSKA, R. (2010). Compliance by Design (CbD) and Compliance Master Plan (CMP) – An Organized Approach to Compliance, Journal of GXP Compliance, v. 14, n. 2, p. 73-82
PORTER, M. (1998). Competitive Advantage: Creating and Sustaining Superior Performance, The Free Press, New York
REUTERS ONLINE, (2009). CBR Pharma Insights: The New Pharmaceutical Sales Force - Key Trends Shaping Future Sales Strategies, Available at: http://www.reuters.com/article/pressRelease/idUS116884+06-Apr
+BW20090406
RITCHIE, L.; BURNES, B.; WHITTLE, P.; HEY, R. (2000). The benefits of reverse logistics: the case of Manchester Royal Infirmary Pharmacy, Supply Chain Management, v. 5, p. 226-34.
SARTORI, G. (2011). Reverse logistics role in securing pharmaceutical supply chain, Reverse Logistics Magazine, Edition 16
SKINNER, L. R.; BRYANT, P. T.; RICHEY R. G. (2008), Examining the Impact of Reverse Logistics Disposition Strategies, International Journal of Physical Distribution & Logistics Management, v. 38, n. 7, p. 518-539.
SOUZA, D.; DANASE, J.; CONSTATINOU, D. (2005). Business Efficiency and Regulatory.
SOUZA, A.; KEELING, D.; PHILLIPS, R. (2007). Improving quality in pharma manufacturing, The McKinsey Quarterly
STEGEMANN, S. (2010). Better by design, Available at http://www.worldpharmaceuticals.net/editorials/017march10/WPF017_better-by-design.pdf
STOCK, J. R. (1998). Development and Implementation of Reverse Logistics Programs, Council of Logistics Management, Annual Conference Proceeding
STOCK, J.; MULKI, J. (2009). Product returns processing: an examination of practices of manufacturers, wholesalers/distributors, and retailers, Journal of Business Logistics, v. 30, n. 1, p. 33-62
STRAUS, A. L.; CORBIN, J. (1994), Grounded Theory Methodology: An Overview, in Denzin Denzin, Norman K. (ed.) Handbook of Qualitative Resarch, London; Sage p. 273-285
SUDDABY, R. (2006). What Grounded Theory is Not, Academy Management Journal, v. 49, n. 4, p. 633-642
SZÉKELY, F.; KNIRSCH, M. (2005). Responsible Leadership and Corporate Social Responsibility: Metrics for Sustainable Performance, European Management Journal, v. 23, n. 6, p. 628-647
TRIM, P.; LEE, Y. (2004). A Reflection on Theory building and Development of Management Knowledge, Management Decision, v. 42, n. 314, p.473-480
YIN, R. (1994). Case Study Research: Design and Methods, Sage, London
YIN, R. (2009). Case Study Research: Design and Methods, Sage, London
YU, L. (2008). Pharmaceutical quality by Design: Product and Process Development, Understanding, and Control, Pharmaceutical Research, v. 25, n. 4.
VELEVA, V.; ELLENBECKER, M. (2001). Indicators of Sustainable Production: Framework and Methodology, Journal of Cleaner Production, v. 9, n. 6, p. 519-49